secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001628280-24-021185
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharmaceuticals Q1 net loss $1.9M; revenue $8.5M
-----------------------------------------------------------

- Net revenue $8.5M; Kristalose $3.2M, Sancuso $1.8M, Vibativ $1.6M, Caldolor $1.5M.
- Net loss $1.9M ($0.14/share); adjusted loss $0.6M ($0.05/share).
- Cash $19M, total assets $82M, liabilities $54M, equity $27M.
- Caldolor highlighted in NOPAIN Act; CMS decision pending for 2025 Medicare reimbursement.
- Ifetroban enrollment underway for Idiopathic Pulmonary Fibrosis trial (128 patients).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828024021185/0001628280-24-021185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828024021185/cpix-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-021185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer